Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort

• Published in: Journal of clinical medicine 2024-04, Vol.13 (7), p.2074
• Main Authors: Panzuto, Francesco, Andrini, Elisa, Lamberti, Giuseppe, Pusceddu, Sara, Rinzivillo, Maria, Gelsomino, Fabio, Raimondi, Alessandra, Bongiovanni, Alberto, Davì, Maria Vittoria, Cives, Mauro, Brizzi, Maria Pia, Persano, Irene, Zatelli, Maria Chiara, Puliafito, Ivana, Tafuto, Salvatore, Campana, Davide
• Format: Article
• Language: English
• Subjects: Chemotherapy; Medical prognosis; Metastasis; Neuroendocrine tumors; Pancreatic cancer; Patients; Risk factors; Statistical analysis; Surgery; Variables
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13072074

The optimal treatment sequencing for advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) is unknown. We performed a multicenter, retrospective study to evaluate the best treatment sequence in terms of progression-free survival to first-line (PFS1) and to second-line (PFS2), and overall survival among patients with advanced, well-differentiated pNETs. : This multicenter study retrospectively analyzed the prospectively collected data of patients with sporadic well-differentiated pNETs who received at least two consecutive therapeutic lines, with evidence of radiological disease progression before change of treatment lines. : Among 201 patients, 40 (19.9%) had a grade 1 and 149 (74.1%) a grade 2 pNET. Primary tumor resection was performed in 98 patients (48.8%). First-line therapy was performed in 128 patients with somatostatin analogs (SSA), 35 received SSA + radioligand therapy (RLT), 21 temozolomide-based chemotherapy, and 17 SSA + targeted therapy. PFS was significantly longer in patients with grade 1 pNETs compared to those with grade 2, in patients who received primary tumor surgery, and in patients treated with RLT compared to other treatments. At multivariate analysis, the use of upfront RLT was independently associated with improved PFS compared to SSA. Second-line therapy was performed in 94 patients with SSA + targeted therapy, 35 received chemotherapy, 45 SSA + RLT, and 27 nonconventional-dose SSA or SSA switch. PFS was significantly longer in patients treated with RLT compared to other treatments. At multivariate analysis, the type of second-line therapy was independently associated with the risk for progression. OS was significantly longer in patients who received primary tumor surgery, with Ki67 < 10%, without extrahepatic disease, and in patients who received SSA-RLT sequence compared to other sequences. : In this large, multicenter study, RLT was associated with better PFS compared to other treatments, and the SSA-RLT sequence was associated with the best survival outcomes in patients with pNETs with Ki67 < 10%. Primary tumor surgery was also associated with improved survival.